The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
Open accessPublished version of a preprint
Abstract
Background: Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization’s Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic. Methods and findings: We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies—those aligned with the WHO Unity protocol—were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 ( p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence ( p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented. Conclusions: In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Wood, S. N. (2011) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2010.00749.x · Cited by 7,537
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827
Feature Selection with the Boruta Package
Kursa, M. B., & Rudnicki, W. R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i11 · Cited by 5,659
WHO Coronavirus Disease (COVID-19) Dashboard
(2020) · Bangladesh Physiotherapy Journal · doi:10.46945/bpj.10.1.03.01 · Cited by 3,806
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Munn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000054 · Cited by 3,131 · cited 1×
“We critically appraised all studies using a modified version of the Joanna Briggs Institute (JBI) checklist for prevalence studies (File F in S1 Materials) [24].”
MethodA global database of COVID-19 vaccinations
Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Rodés-Guirao, L. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01122-8 · Cited by 1,974 · cited 1×
“During 2021, many regions have experienced third and fourth waves of SARS-CoV-2 infection [1]; concurrently, some countries have vaccinated most residents, while others remain unable to achieve high vaccine coverage due to challenges with supply and uptake [5].”
BackgroundCoronavirus Pandemic (COVID-19): Emotional Toll Analysis on Twitter
Alowibdi, J. S., Alshdadi, A. A., Daud, A., Dessouky, M. M., & Alhazmi, E. A. (2021) · International Journal on Semantic Web and Information Systems · doi:10.4018/ijswis.2021040101 · Cited by 1,530
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · cited 1×
“There are several possible explanations for lower seroprevalence in children: milder infections, which are generally associated with lower antibody titers [50]; school closures; and ineligibility for vaccination.”
BackgroundInferring the effectiveness of government interventions against COVID-19
Brauner, J. M., Mindermann, S., Sharma, M., Johnston, D., Salvatier, J., Gavenčiak, T., Stephenson, A. B., Leech, G., Altman, G., Mikulik, V., et al. (2021) · Science · doi:10.1126/science.abd9338 · Cited by 1,065
Evidence for antibody as a protective correlate for COVID-19 vaccines
Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R., Dull, P., & Plotkin, S. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.063 · Cited by 870
Talic, S., Shah, S., Wild, H., Gasevic, D., Maharaj, A., Ademi, Z., Li, X., Xu, W., Mesa-Eguiagaray, I., Rostron, J., et al. (2021) · BMJ · doi:10.1136/bmj-2021-068302 · Cited by 787
Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00575-4 · Cited by 586 · cited 1×
“Lower seroprevalence in adults 60+ could be explained by immunosenescence that can lead to quicker seroreversion [49] higher mortality and hence a lower proportion of individuals with evidence of past infection, gaps in vaccine access, or more cautious behaviour resulting in fewer infections in this age group.”
BackgroundHow are systematic reviews of prevalence conducted? A methodological study
on behalf of the Prevalence Estimates Reviews – Systematic Review Methodology Group (PERSyst), Borges Migliavaca, C., Stein, C., Colpani, V., Barker, T. H., Munn, Z., & Falavigna, M. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-00975-3 · Cited by 359
Bewley, K. R., Coombes, N. S., Gagnon, L., McInroy, L., Baker, N., Shaik, I., St-Jean, J. R., St-Amant, N., Buttigieg, K. R., Humphries, H. E., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00536-y · Cited by 293
Quality assessment of prevalence studies: a systematic review
Migliavaca, C. B., Stein, C., Colpani, V., Munn, Z., & Falavigna, M. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.06.039 · Cited by 253
Byambasuren, O., Dobler, C. C., Bell, K., Rojas, D. P., Clark, J., McLaws, M.-L., & Glasziou, P. (2021) · PLOS ONE · doi:10.1371/journal.pone.0248946 · Cited by 250
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
Bobrovitz, N., Arora, R. K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., Chen, J., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252617 · Cited by 246 · cited 2×
“Our results add global representation and principled estimation of changes in seroprevalence over time as compared to previous evidence syntheses [9,11,12].”
BackgroundResultSelf-citationSerological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
Chen, X., Chen, Z., Azman, A. S., Deng, X., Sun, R., Zhao, Z., Zheng, N., Chen, X., Lu, W., Zhuang, T., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00026-7 · Cited by 239
Tso, F. Y., Lidenge, S. J., Peña, P. B., Clegg, A. A., Ngowi, J. R., Mwaiselage, J., Ngalamika, O., Julius, P., West, J. T., & Wood, C. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.104 · Cited by 234
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
Wei, J., Matthews, P. C., Stoesser, N. E., Maddox, T., Lorenzi, L., Studley, R., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26479-2 · Cited by 143
Vitale, J., Mumoli, N., Clerici, P., Paschale, M. D., Evangelista, I., Cei, M., & Mazzone, A. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2959 · Cited by 140
Murhekar, M. V., Bhatnagar, T., Thangaraj, J. W. V., Saravanakumar, V., Kumar, M. S., Selvaraju, S., Rade, K., Kumar, C. P. G., Sabarinathan, R., Turuk, A., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.040 · Cited by 134
The Effect of Containment Measures on the COVID-19 Pandemic
Deb, P., Furceri, D., Ostry, J. D., & Tawk, N. (2020) · IMF Working Paper · doi:10.5089/9781513550268.001 · Cited by 133
Iesa, M. A. M., Osman, M. E. M., Hassan, M., Dirar, A. I., Abuzeid, N. M. K., Mancuso, J. J., Pandey, R., Mohammed, A. A., Borad, M. J., Babiker, H. M., et al. (2020) · New Microbes and New Infections · doi:10.1016/j.nmni.2020.100817 · Cited by 84
A Global Immunological Observatory to meet a time of pandemics
Mina, M. J., Metcalf, C. J. E., McDermott, A. B., Douek, D. C., Farrar, J., & Grenfell, B. T. (2020) · eLife · doi:10.7554/elife.58989 · Cited by 82
Bergeri, I., Lewis, H. C., Subissi, L., Nardone, A., Valenciano, M., Cheng, B., Glonti, K., Williams, B., Abejirinde, I. O., Simniceanu, A., et al. (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12915 · Cited by 78
Self-citationUpdate on SARS-CoV-2 seroprevalence: regional and worldwide
Rostami, A., Sepidarkish, M., Fazlzadeh, A., Mokdad, A. H., Sattarnezhad, A., Esfandyari, S., Riahi, S. M., Mollalo, A., Dooki, M. E., Bayani, M., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.019 · Cited by 73
Barrie, M. B., Lakoh, S., Kelly, J. D., Kanu, J. S., Squire, J. S., Koroma, Z., Bah, S., Sankoh, O. A., Brima, A. S., Ansumana, R., et al. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2021-007271 · Cited by 63
Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic
Steinhardt, L. C., Ige, F. A., Iriemenam, N. C., Greby, S. M., Hamada, Y., Uwandu, M., Aniedobe, M., Stafford, K. A., Abimiku, A., Mba, N., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00514-21 · Cited by 55
Adapting Serosurveys for the SARS-CoV-2 Vaccine Era
Duarte, N., Yanes‐Lane, M., Arora, R. K., Bobrovitz, N., Liu, M., Bego, M. G., Yan, T., Cao, C., Gurry, C., Hankins, C. A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab632 · Cited by 46
Self-citationSuthar, A. B., Schubert, S. L., Garon, J. R., Couture, A., Brown, A. M., & Charania, S. (2021) · Emerging infectious diseases · doi:10.3201/eid2801.211082 · Cited by 32
Laing, E. D., Epsi, N. J., Richard, S. A., Samuels, E. C., Wang, W., Vassell, R. A., Ewing, D. F., Herrup, R., Sterling, S. L., Lindholm, D. A., et al. (2021) · medRxiv · doi:10.1101/2021.04.27.21256207 · Cited by 24
Murhekar, M. V., Bhatnagar, T., Thangaraj, J. W. V., Saravanakumar, V., Kumar, M. S., Selvaraju, S., Rade, K., Kumar, C. P. G., Sabarinathan, R., Turuk, A., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3797589 · Cited by 23
Al-Abri, S., Wahaibi, A. S. A., Al-Kindi, H., Kurup, P. J., Al-Maqbali, A., Almayahi, Z. K., Al-Tobi, M. H., Al-Katheri, S. H., Albusaidi, S., Al-Sukaiti, M. H., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.062 · Cited by 20
Bobrovitz, N., Noël, K. C., Li, Z., Cao, C., Deveaux, G., Selemon, A., Clifton, D. A., Yanes‐Lane, M., Yan, T., & Arora, R. K. (2023) · Research Synthesis Methods · doi:10.1002/jrsm.1620 · Cited by 20
Self-citationvan den Beld, M. J. C., Murk, J., Kluytmans, J. A. J. W., Koopmans, M., Reimerink, J. H. J., van Loo, I. H. M., Wegdam-Blans, M. C. A., Zaaijer, H. L., SARS-CoV-2, S. W. F., GeurtsvanKessel, C. H., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00767-21 · Cited by 19
Ren, Z.-X., Nishimura, M., Tjan, L. H., Furukawa, K., Kurahashi, Y., Sutandhio, S., Aoki, K., Hasegawa, N., Arii, J., Uto, K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266270 · Cited by 19
Dehgani‐Mobaraki, P., Wang, C., Floridi, A., Floridi, E., Dawoodi, S., & Zaidi, A. K. (2022) · Virology · doi:10.1016/j.virol.2022.12.003 · Cited by 15
WHO Unity Global SARS-CoV-2 Seroepidemiological Investigations
Barr, B. A. T., Herman-Roloff, A., Mburu, M., Murnane, P. M., Sang, N., Bukusi, E. A., Oele, E., Odhiambo, A., Lewis-Kulzer, J., Onyango, C. O., et al. (2022) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.6075687 · Cited by 3
WHO Unity Sero-Epidemiological Studies Early Results Submission Template - Blank
Ware, H., Whelan, M. G., Li, Z., Cheng, B., Valenciano, M., Lewis, H. C., Nardone, A., Subissi, L., Arora, R. K., & Bergeri, I. (2021) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.5719532 · Cited by 2
Self-citation
Research works printed but not linked: 18
- N Bobrovitz, 2021, A systematic review and meta-analysis of SARS-CoV-2 seroprevalence studies aligned with the WHO population-based sero-epidemiological ‘Unity’ protocol CRD42020183634, PROSPERO
- SeroTracker Group, 2022, SeroTracker: Our Data (Our Protocol), Airtable
- COVID-19 Global Humanitarian Response Plan, 2020, United Nations Office for the Coordination of Humanitarian Affairs
- M Morgan, Sensitivity and specificity of multiple tests, In: Radiopaedia
- NRL, 2021, WHO COVID Evaluations Summary of Results, nrlquality
- HTG Aus AGD of, 2021, Post market review of COVID-19 point-of-care tests, Therapeutic Goods Administration (TGA). Australian Government Department of Health
- FIND, 2021, FIND evaluation of SARS-CoV-2 antibody (Ab) detection tests, FIND: Diagnosis for All
- N Bobrovitz, 2021, SeroTracker-ROB: reproducible decision rules for risk of bias assessment of seroprevalence studies, Epidemiology
- World Health Organization, 2021, Regional offices
- The World Bank, 2021, World Bank Country and Lending Groups
- World Health Organization, London School of Hygiene and Tropical Medicine, 2021, Public Health and Social Measures
- J Higgins, 2021, Cochrane Handbook for Systematic Reviews of Interventions (version 6.2), Cochrane
- WHO Headquarters (HQ), 2020, WHO COVID-19 Case definition
- H Ritchie, 2020, Coronavirus Pandemic (COVID-19), Our World in Data
- Institute for Health metrics and Evaluation (IHME), 2021, COVID-19: Estimating the historical time series of infections
- Institute for Health metrics and Evaluation (IHME), 2021, COVID-19 Estimates
- Puya-Dehgani-Mobaraki, 2022, Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response, Infectious Diseases (except HIV/AIDS)
- CJE Metcalf, 2017, Opportunities and challenges of a world serum bank–authors’ reply, Lancet, 389, 252, 10.1016/S0140-6736(17)30054-5 · doi:10.1016/s0140-6736(17)30054-5
Cited by
Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z., Issa, H., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00801-5 · Cited by 614
Self-citationLevin, A. T., Owusu-Boaitey, N., Pugh, S., Fosdick, B. K., Zwi, A. B., Malani, A., Soman, S., Besançon, L., Kashnitsky, I., Ganesh, S., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-008477 · Cited by 208
Lewis, H., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., et al. (2022) · doi:10.1101/2022.02.14.22270934 · Cited by 177
Self-citationWang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68
Automation of Systematic Reviews with Large Language Models
Cao, C., Arora, R., Cento, P., Budak, A., Manta, K., Farahani, E., Cecere, M., Selemon, A., Sang, J., Gong, L. X., et al. (2025) · medRxiv · doi:10.1101/2025.06.13.25329541 · Cited by 33
Self-citation
Metadata
- Authors
- Bergeri, I., Whelan, M. G., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., Al Ariqi, L., Rashidian, A., Okeibunor, J., Azim, T., Wijesinghe, P., Le, L.-V., Vaughan, A., Pebody, R., Vicari, A., Yan, T., Yanes-Lane, M., Cao, C., Clifton, D. A., Cheng, M. P., Papenburg, J., Buckeridge, D., Bobrovitz, N., Arora, R. K., Van Kerkhove, M. D., & Unity Studies Collaborator Group
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-11-10
- Volume
- 19
- Issue
- 11
- Pages
- e1004107
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W4308706077
- Cited by
- 310
- References
- 45
- FWCI
- 13.72
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- WHO COVID-19 Solidarity Response Fund
- German Federal Ministry of Health COVID-19 Research and Development Fund
- World Health Organisation
- Canada’s COVID-19 Immunity Task Force through the Public Health Agency of Canada (2021-HQ-000056)
- Canadian Medical Association Joule Innovation Fund
- Robert Koch Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.